What is claimed is:
1. An isolated polynucleotide encoding a zsig63 polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 16 (Arg) to amino acid number 37 (Ser);
(b) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 38 (Leu) to amino acid number 126 (Ala);
(c) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 127 (Pro) to amino acid number 219 (Gln);
(d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 16 (Arg) to amino acid number 219 (Gin); and
(e) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 1 (Met) to amino acid number 219 (Gln).
2. An isolated polynucleotide according to claim 1, wherein the zsig63 polypeptide comprises a sequence of amino acid residues selected from the group consisting of:
(a) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 16 (Arg) to amino acid number 37 (Ser);
(b) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 38 (Leu) to amino acid number 126 (Ala);
(c) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 127 (Pro) to amino acid number 219 (Gln);
(d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 16 (Arg) to amino acid number 219 (Gln); and
(e) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 1 (Met) to amino acid number 219 (Gln).
3. An isolated polynucleotide according to claim 1, wherein the polynucleotide is selected from the group consisting of:
(a) a polynucleotide sequence as shown in SEQ ID NO:1 from nucleotide 173 to nucleotide 784;
(b) a polynucleotide sequence as shown in SEQ ID NO:1 from nucleotide 128 to nucleotide 784; and
(c) a polynucleotide sequence complementary to (a) or (b).
4. An isolated polynucleotide sequence according to claim 1, wherein the polynucleotide comprises nucleotide 1 to nucleotide 657 of SEQ ID NO:3.
5. An expression vector comprising the following operably linked elements:
a transcription promoter;
a DNA segment encoding a zsig63 polypeptide comprising an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:2 from amino acid number 16 (Arg) to amino acid number 219 (Gln); and
a transcription terminator.
6. An expression vector according to claim 5, further comprising a secretory signal sequence operably linked to the DNA segment.
7. A cultured cell into which has been introduced an expression vector according to claim 5, wherein the cell expresses a polypeptide encoded by the DNA segment.
8. A DNA construct encoding a fusion protein, the DNA construct comprising:
a first DNA segment encoding a polypeptide selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO: 2 from residue number 1 (Met) to residue number 15 (Ala);
(b) the amino acid sequence of SEQ ID NO: 2 from residue number 16 (Arg) to residue number 37 (Ser).;
(c) the amino acid sequence of SEQ ID NO: 2 from residue number 38 (Leu) to residue number 126 (Ala);
(d) the amino acid sequence of SEQ ID NO: 2 from residue number 127 (Pro) to residue number 219 (Gln); and
(e) the amino acid sequence of SEQ ID NO:2 from residue number 16 (Arg) to residue number 219 (Gln); and
at least one other DNA segment encoding an additional polypeptide,
wherein the first and other DNA segments are connected in-frame; and
encode the fusion protein.
9. A fusion protein produced by a method comprising:
culturing a host cell into which has been introduced a vector comprising the following operably linked elements:
(a) a transcriptional promoter;
(b) a DNA construct encoding a fusion protein according to claim 8; and
(c) a transcriptional terminator; and
recovering the protein encoded by the DNA segment.
10. An isolated zsig63 polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 16 (Arg) to amino acid number 37 (Ser);
(b) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 38 (Leu) to amino acid number 126 (Ala);
(c) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 127 (Pro) to amino acid number 219 (Gln);
(d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 16 (Arg) to amino acid number 219 (Gln); and
(e) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 1 (Met) to amino acid number 219 (Gln).
11. An isolated zsig63 polypeptide according to claim 10, wherein the polypeptide comprises a sequence of amino acid residues selected from the group consisting of:
(a) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 16 (Arg) to amino acid number 37 (Ser);
(b) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 38 (Leu) to amino acid number 126 (Ala);
(c) the amino acid sequence as shown in SEQ ID NO: 2 from amino acid number 127 (Pro) to amino acid number 219 (Gln);
(d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 16 (Arg) to amino acid number 219 (Gln); and
(e) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 1 (Met) to amino acid number 219 (Gln).
12. A method of producing a zsig63 polypeptide comprising:
culturing a cell according to claim 7; and
isolating the zsig63 polypeptide produced by the cell.
13. A method of detecting, in a test sample, the presence of an antagonist of zsig63 protein activity, comprising:
transfecting a zsig63-responsive cell, with a reporter gene construct that is responsive to a zsig63-stimulated cellular pathway; and
producing a zsig63 polypeptide by the method of claim 12; and
adding the zsig63 polypeptide to the cell, in the presence and absence of a test sample; and
comparing levels of response to the zsig63 polypeptide, in the presence and absence of the test sample, by a biological or biochemical assay; and
determining from the comparison, the presence of the antagonist of zsig63 activity in the test sample.
14. A method of detecting, in a test sample, the presence of an agonist of zsig63 protein activity, comprising:
transfecting a zsig63-responsive cell, with a reporter gene construct that is responsive to a zsig63-stimulated cellular pathway; and
adding a test sample; and
comparing levels of response in the presence and absence of the test sample, by a biological or biochemical assay; and
determining from the comparison, the presence of the agonist of zsig63 activity in the test sample.
15. A method of producing an antibody to zsig63 polypeptide comprising the following steps in order:
inoculating an animal with a polypeptide selected from the group consisting of:
(a) a polypeptide consisting of 9 to 204 amino acids, wherein the polypeptide consists of a contiguous sequence of amino acids in SEQ ID NO:2 from amino acid number 16 (Ala) to amino acid number 219 (Gln); and
(b) a polypeptide according to claim 10;
(c) a polypeptide comprising amino acid number 16 (Arg) to 37 (Ser) of SEQ ID NO:2;
(d) a polypeptide comprising amino acid number 38 (Leu) to 126 (Ala) of SEQ ID NO:2;
(e) a polypeptide comprising amino acid number 127 (Pro) to 219 (Gln) of SEQ ID NO:2;
(f) a polypeptide comprising amino acid number 16 (Arg) to amino acid number 219 (Gln) of SEQ ID NO:2;
(g) a polypeptide comprising amino acid number 1 (Met) to amino acid number 219 (Gln) of SEQ ID NO:2;
(h) a polypeptide comprising amino acid number 14 (Phe) to 19 (Arg) of SEQ ID NO:2;
(i) a polypeptide comprising amino acid number 16 (Arg) to 21 (Phe) of SEQ ID NO:2;
(j) a polypeptide comprising amino acid number 24 (Gly) to 29 (Asp) of SEQ ID NO:2;
(k) a polypeptide comprising amino acid number 25 (Glu) to 30 (Asp) of SEQ ID NO:2;
(l) a polypeptide comprising amino acid number 187Glu) to 192 (Glu) of SEQ ID NO:2;
(m) a polypeptide comprising amino acid number 24 (Gly) to 33 (Pro) of SEQ ID NO:2;
(n) a polypeptide comprising amino acid number 17 (Lys) to 33 (Pro) of SEQ ID NO:2;
(o) a polypeptide comprising amino acid number 66 (Thr) to 73 (Pro) of SEQ ID NO:2;
(p) a polypeptide comprising amino acid number 103 (Pro) to 108 (Gly) of SEQ ID NO:2;
(q) a polypeptide comprising amino acid number 190 (Ala) to 197 (Glu) of SEQ ID NO:2;
(r) a polypeptide comprising amino acid number 202 (Lys) to 215 (Gly) of SEQ ID NO:2; and
(s) a polypeptide comprising amino acid number 190 (Ala) to 215 (Glu) of SEQ ID NO:2; and
wherein the polypeptide elicits an immune response in the animal to produce the antibody; and
isolating the antibody from the animal.
16. An antibody produced by the method of claim 15, which binds to a zsig63 polypeptide.
17. The antibody of claim 16, wherein the antibody is a monoclonal antibody.
18. An antibody that binds to a polypeptide of claim 10.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
I claim:
1. A vortex nozzle, comprising:
a nozzle body including a passageway therethrough and a plurality of ports that inlet a fluid flow into the passageway; and
an end cap attached to the nozzle body.
2. The vortex nozzle according to claim 1 wherein the passageway is a tapered passageway.
3. The vortex nozzle according to claim 2 wherein the tapered passageway includes an inlet side and an outlet side.
4. The vortex nozzle according to claim 3 wherein the inlet side of the tapered passageway includes a taper at an angle substantially equal to the angle of the taper of the tapered passageway.
5. The vortex nozzle according to claim 2 wherein each of the plurality of ports is tangential to the tapered passageway .
6. The vortex nozzle according to claim 2 wherein each of the plurality of ports enters the tapered passageway at an angle substantially equal to the angle of the taper of the tapered passageway.
7. The vortex nozzle according to claim 3 wherein the cross-sectional area of each of the plurality of ports is less than the cross-sectional area of the inlet side of the tapered passageway.
8. The vortex nozzle according to claim 1 wherein the plurality of ports is substantially equally spaced radially about the nozzle body.
9. The vortex nozzle according to claim 1 wherein the plurality of ports is substantially trapezoidal in shape.
10. The vortex nozzle according to claim 2 wherein the end cap includes an inner face having a taper at an angle substantially equal to the angle of the taper of the tapered passageway.
11. The vortex nozzle according to claim 1 wherein the end cap includes a boss that extends into the passageway and is adapted to adjust force vector components of the fluid flow entering the passageway.
12. The vortex nozzle according to claim 1 wherein the nozzle body is substantially cylindrical in shape and includes a shoulder having a raised portion.
13. A vortex nozzle, comprising:
a nozzle body including a passageway therethrough and a port that inlets a fluid flow into the passageway, whereby the port is tangential to the passageway; and
an end cap attached to the nozzle body.
14. The vortex nozzle according to claim 13 wherein the passageway is a tapered passageway.
15. The vortex nozzle according to claim 14 wherein the tapered passageway includes an inlet side and an outlet side.
16. The vortex nozzle according to claim 15 wherein the inlet side of the tapered passageway includes a taper at an angle substantially equal to the angle of the taper of the tapered passageway.
17. The vortex nozzle according to claim 14 wherein the port is tangential to the tapered passageway.
18. The vortex nozzle according to claim 14 wherein the port enters the tapered passageway at an angle substantially equal to the angle of the taper of the tapered passageway.
19. The vortex nozzle according to claim 15 wherein the cross-sectional area of the port is less than the cross-sectional area of the inlet side of the tapered passageway.
20. The vortex nozzle according to claim 13 wherein the port is substantially trapezoidal in shape.
21. The vortex nozzle according to claim 14 wherein the end cap includes an inner face having a taper at an angle substantially equal to the angle of the taper of the tapered passageway.
22. The vortex nozzle according to claim 13 wherein the end cap includes a boss that extends into the passageway and is adapted to adjust force vector components of the fluid flow entering the passageway.
23. The vortex nozzle according to claim 13 wherein the nozzle body is substantially cylindrical in shape and includes a shoulder having a raised portion.
24. A fluid treating apparatus, comprising:
a first vortex nozzle including a passageway therethrough and a plurality of ports that inlet a first fluid flow into the passageway, whereby the first vortex nozzle imparts a rotation to the first fluid flow thereby creating a first rotated fluid flow; and
a second vortex nozzle positioned in opposed relation the first vortex nozzle, the second vortex nozzle including a passageway therethrough and a plurality of ports that inlet a second fluid flow into the passageway, whereby the second vortex nozzle imparts a rotation to the second fluid flow thereby creating a second rotated fluid flow collided with the first rotated fluid flow.
25. A fluid treating apparatus, comprising:
a first vortex nozzle including a passageway therethrough and a port that inlets a first fluid flow tangentially to the passageway, whereby the first vortex nozzle imparts a rotation to the first fluid flow thereby creating a first rotated fluid flow; and
a second vortex nozzle positioned in opposed relation the first vortex nozzle, the second vortex nozzle including a passageway therethrough and a port that inlets a second fluid flow tangentially to the passageway, whereby the second vortex nozzle imparts a rotation to the second fluid flow thereby creating a second rotated fluid flow collided with the first rotated fluid flow.
26. The fluid treating apparatus according to claim 25 wherein the port of the first vortex nozzle inlets the first fluid flow normal to the passageway.
27. The fluid treating apparatus according to claim 25 wherein the port of the second vortex nozzle inlets the second fluid flow normal to the passageway.
28. A method of treating a fluid, comprising:
positioning a first vortex nozzle in opposed relation to a second vortex nozzle;
inletting a first fluid flow into a passageway of the first vortex nozzle via a plurality of ports of the first vortex nozzle, whereby the first vortex nozzle imparts a rotation to the first fluid flow thereby creating a first rotated fluid flow; and
inletting a second fluid flow into a passageway of the second vortex nozzle via a plurality of ports of the second vortex nozzle, whereby the second vortex nozzle imparts a rotation to the second fluid flow thereby creating a second rotated fluid flow collided with the first rotated fluid flow.
29. A method of treating a fluid, comprising:
positioning a first vortex nozzle in opposed relation to a second vortex nozzle;
inletting a first fluid flow tangentially into a passageway of the first vortex nozzle via a port of the first vortex nozzle, whereby the first vortex nozzle imparts a rotation to the first fluid flow thereby creating a first rotated fluid flow; and
inletting a second fluid flow tangentially into a passageway of the second vortex nozzle via a port of the second vortex nozzle, whereby the second vortex nozzle imparts a rotation to the second fluid flow thereby creating a second rotated fluid flow collided with the first rotated fluid flow.
30. The method according to claim 29, further comprising inletting the first fluid flow normal to the passageway of the first vortex nozzle via the port of the first vortex nozzle.
31. The method according to claim 29, further comprising inletting the second fluid flow normal to the passageway of the second vortex nozzle via the port of the second vortex nozzle.
32. A method of rotating a fluid, comprising:
inletting a fluid flow into a passageway of a vortex nozzle via a plurality of ports; and
rotating the fluid flow in the passageway.
33. The method according to claim 32, further comprising inletting the fluid flow tangentially to the passageway.
34. The method according to claim 32, wherein the passageway is tapered, and the fluid flow is inlet at an angle substantially equal to the taper.
35. A method of rotating a fluid, comprising:
inletting a fluid flow tangentially into a passageway of a vortex nozzle; and
rotating the fluid flow in the passageway.
36. The method according to claim 35, further comprising inletting the fluid flow normal to the passageway.
37. The method according to claim 35, wherein the passageway is tapered, and the fluid flow is inlet at an angle substantially equal to the taper.
38. A vortex nozzle, comprising:
a nozzle body including a passageway;
at least a segment of the passageway being tapered; and
a plurality of ports that inlet a fluid flow into the passageway.
39. The vortex nozzle according to claim 38, wherein at least one of the plurality of ports is tangential to the tapered passageway.
40. The vortex nozzle according to claim 38, wherein at least one of the plurality of ports enters the tapered passageway at an angle substantially equal to the angle of the taper of the tapered passageway.
41. The vortex nozzle according to claim 38, wherein the nozzle body is substantially cylindrical in shape and includes a shoulder having a raised portion.
42. A vortex nozzle, comprising:
a nozzle body including a passageway;
at least a segment of the passageway being tapered; and
a port that inlets a fluid flow into the passageway, the port being tangential to the passageway.
43. The vortex nozzle according to claim 42, wherein the port enters the tapered passageway at an angle substantially equal to the angle of the taper of the tapered passageway.
44. The vortex nozzle according to claim 42, wherein the nozzle body is substantially cylindrical in shape and includes a shoulder having a raised portion.
45. A fluid treatment system, comprising:
a pump;
two opposed vortex nozzles;
a manifold for receiving fluid from the pump and directing it to the nozzles; and
a frame, wherein the pump, nozzles, and manifold are mounted to the frame.
46. The system according to claim 45, wherein the manifold comprises two elbows, and each of the elbows comprises two elbow fittings.
47. A fluid treatment system, comprising:
a pump;
two opposed vortex nozzles; and
a manifold for receiving fluid from the pump and directing it to the nozzles, wherein
the manifold comprises two elbows, and each of the elbows comprises two elbow fittings.
48. The fluid treatment system according to claim 47, further comprising a frame on which the nozzles, pump, and manifold are mounted.